^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Published date:
01/28/2023
Excerpt:
This was a single-center retrospective study of adult patients diagnosed with first recurrence GBM and received pembrolizumab or nivolumab with or without concurrent bevacizumab....NGS of samples from 15 patients identified EGFR amplification at initial diagnosis and at any time point to be associated with worse survival after ICI (HR 12.2, 95% CI 1.37-108, p = 0.025 and HR 3.92, 95% CI 1.03-14.9, p = 0.045, respectively)…molecular sequencing identified EGFR amplification as associated with worse survival.
DOI:
10.1007/s00262-023-03381-y
